Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib

Blood (2023) 142 (Supplement 1): 3171.

https://doi.org/10.1182/blood-2023-179142

Published: 2023

Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Blood (2023) 142 (Supplement 1): 869.

https://doi.org/10.1182/blood-2023-187740

Published: 2023

Journal Articles

Relationship between Sarcopenia and the Heterogeneity and Microenvironment of Acute Myeloid Leukemia Based on Single-Cell Transcriptome Sequencing

Qian Sun, Wenjie Liu, Ming Hong, Yu Zhu, Jianyong Li, Sixuan Qian

Blood (2023) 142 (Supplement 1): 6026.

https://doi.org/10.1182/blood-2023-173220

Published: 2023

Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2023-179073

Published: 2023

Journal Articles

High-Dose Idarubicin Plus Busulfan As Conditioning Regimen to Autologous Stem Cell Transplantation Improves Prognosis in Patients with Favorable and Intermediate-Risk AML

Ming Hong, Wenjie Liu, Qian Sun, Qian Sun, Sixuan Qian, Jianyong Li

Blood (2022) 140 (Supplement 1): 12926–12927.

https://doi.org/10.1182/blood-2022-166638

Published: 2022

Journal Articles

The Prognosis of Intermediate- and High-Risk Young AML Patients Who Did Not Receive Allo-HSCT Treated with Intensive Chemotherapy Is Not Superior to That of Elderly AML Patients Treated with the D-CAG Regimen

Ming Hong, Qian Sun, Wenjie Liu, Han Zhu, Yu Zhu, Jianyong Li, Sixuan Qian

Blood (2021) 138 (Supplement 1): 1228.

https://doi.org/10.1182/blood-2021-149060

Published: 2021

Journal Articles

TP53 Abnormality in Myelodysplastic Syndrome

Fei Huang, Yu Chen, Yuxing Zhu, Chun Qiao, Sixuan Qian, Jianyong Li, MD, Wenyi Shen, MD

Blood (2019) 134 (Supplement_1): 5410.

https://doi.org/10.1182/blood-2019-128054

Published: 2019

Journal Articles

Sarcopenia As a Significant Prognostic Factor in Acute Myeloid Leukemia: Validation of a Novel Scoring System

Qian Sun, Hong Ming, Sixuan Qian, Jian-Yong Li, MD PhD

Blood (2019) 134 (Supplement_1): 5896.

https://doi.org/10.1182/blood-2019-130517

Published: 2019

Journal Articles

Functional Evaluation and Mechanism Study of Kel As an Oncogenic Driver in Acute Erythroleukemia

Hui Jin, Jianyong Li, MD, Zijuan Wu, Handong Sun, Wenjie Liu, MD, Yanfeng Liu, PhD, Ming Hong, MD PhD, Sixuan Qian, Wei Xu, MD PhD

Blood (2019) 134 (Supplement_1): 1246.

https://doi.org/10.1182/blood-2019-124607

Published: 2019

Journal Articles

The Synergy of Vitamin C with Decitabine Activates TET2 in Leukemic Cells and Significantly Improves Overall Survival in Elderly Patients with Acute Myeloid Leukemia

Huihui Zhao, Zhu Huayuan, Zhu Yu, Jianyong Li, MD PhD, Sixuan Qian, PhD MD

Blood (2017) 130 (Supplement 1): 1339.

https://doi.org/10.1182/blood.V130.Suppl_1.1339.1339

Published: 2017

Journal Articles

TP53-Induced Glycolysis and Apoptosis Regulator Protects from Spontaneous Apoptosis and Predicts Poor Prognosis in Chronic Lymphocytic Leukemia

Ming Hong, Yi Xia, Yu Zhu, MD, Huihui Zhao, Yue Xie, Lei Fan, MD, PhD, Li Wang, Kourong Miao, MD, Wei Wu, Huayuan Zhu, MD, Yaoyu Chen, Wei Xu, Sixuan Qian, Jianyong Li

Blood (2016) 128 (22): 5101.

https://doi.org/10.1182/blood.V128.22.5101.5101

Published: 2016

Journal Articles

Baseline Characteristics and Early Monitoring of Chinese CML Patients Treated with Dasatinib: Report from a Multicenter, Observational, Registry-Based Study

Qian Jiang, MD, Jianda Hu, MD PhD, Fang Zheng, Xin Du, Li Meng, Depei Wu, MD PhD, Bingcheng Liu, Zhuogang Liu, Jun Ma, MD, Ming Hou, MD PhD, Sixuan Qian, Qingshu Zeng, Yu Hu, Xiaojun Huang

Blood (2016) 128 (22): 5439.

https://doi.org/10.1182/blood.V128.22.5439.5439

Published: 2016

Journal Articles

PFKFB3 Is a Crucial Target in the Treatment of Tyrosine Kinase Inhibitor Resistant Chronic Myelogenous Leukemia

Yu Zhu, Jianyong Li, Chun Qiao, Yi Shan, MD, Sixuan Qian, Yaoyu Chen, Ming Hong, Huihui Zhao, Huapeng LI, Xuejun Zhu, Yang Zhongfa

Blood (2016) 128 (22): 3936.

https://doi.org/10.1182/blood.V128.22.3936.3936

Published: 2016

Journal Articles

Continuous High-Dose Idarubicin and Busulfan As Conditioning Regimen for Chinese Patients with Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation

Hong Ming, Sixuan Qian, Liu Peng, Wu Hanxin, Qiu Hongxia, Lu Hua, Zhang Sujiang, Xu Wei

Blood (2012) 120 (21): 4539.

https://doi.org/10.1182/blood.V120.21.4539.4539

Published: 2012

Journal Articles

Decitabine, low-dose cytarabine and aclarubicin combination with granulocyte colony-stimulating factor priming for the induction chemotherapy of older patients with myelodysplastic syndromes and acute myeloid leukemia

Sixuan Qian, Run Zhang, M.D., Yu Zhu, Hua Lu, Peng Liu, Hongxia Qiu, Hanxin Wu, Ming Hong, Jianyong Li

Blood (2012) 120 (21): 1520.

https://doi.org/10.1182/blood.V120.21.1520.1520

Published: 2012

Journal Articles

Effect of Low-Dose Cytarabine and Aclarubicin in Combination with Decitabine and Granulocyte Colony-Stimulating Factor Priming on the Outcome of Patients with Myeloid neoplasms

SiXuan Qian, Peng Liu, Jianyong Li, MD, PhD

Blood (2011) 118 (21): 5047.

https://doi.org/10.1182/blood.V118.21.5047.5047

Published: 2011

Journal Articles

Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses.

Jianyong Li, MD, PhD, Sixuan Qian, Jiye Aa, Guangji Wang, Sujiang Zhang, Lingna Ni, Hanxin Wu, Hua Lu

Blood (2010) 116 (21): 3379.

https://doi.org/10.1182/blood.V116.21.3379.3379

Published: 2010

Journal Articles

High-Dose Etoposide with Granulocyte Colony-Stimulating Factor for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Hematologic Malignancies.

Xiao-yan Zhang, Jianyong Li, MD, PhD, Sixuan Qian, Hongxia Qiu, Han-xin Wu, Hua Lu, Wei Xu, MD, PhD, Ming Hong

Blood (2009) 114 (22): 4235.

https://doi.org/10.1182/blood.V114.22.4235.4235

Published: 2009

Journal Articles

Cotransplantation of HLA-Identical Mesenchymal Stem Cells and Hematopoietic Stem Cells in Chinese Patients with Hematologic Diseases.

Xiaoyan Zhang, Jianyong Li, Kejiang Cao, Hanxin Wu, Hua Lu, Peng Liu, Sixuan Qian, Wei Xu, Wenyi Shen, Yu Zhu

Blood (2007) 110 (11): 5061.

https://doi.org/10.1182/blood.V110.11.5061.5061

Published: 2007

Journal Articles

HLA-Haploidentical Related Hematopoietic Stem Cell Transplantation and Mesenchymal Stem Cell Transplantation in Patients with Hematologic Malignancies.

Xiaoyan Zhang, MD, PhD, Jianyong Li, M.D, Ph.D, Kejiang Cao, M.D, Ph.D, Hanxin Wu, M.D, Hua Lu, M.D, Sixuan Qian, M.D, Wei Xu, M.D, Ph.D, Peng Liu, M.D, Ph.D, Lijuan Meng, M.D, Yu Zhu, M.D

Blood (2006) 108 (11): 5408.

https://doi.org/10.1182/blood.V108.11.5408.5408

Published: 2006

NARROW

Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Relationship between Sarcopenia and the Heterogeneity and Microenvironment of Acute Myeloid Leukemia Based on Single-Cell Transcriptome Sequencing

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

High-Dose Idarubicin Plus Busulfan As Conditioning Regimen to Autologous Stem Cell Transplantation Improves Prognosis in Patients with Favorable and Intermediate-Risk AML

The Prognosis of Intermediate- and High-Risk Young AML Patients Who Did Not Receive Allo-HSCT Treated with Intensive Chemotherapy Is Not Superior to That of Elderly AML Patients Treated with the D-CAG Regimen

TP53 Abnormality in Myelodysplastic Syndrome

Sarcopenia As a Significant Prognostic Factor in Acute Myeloid Leukemia: Validation of a Novel Scoring System

Functional Evaluation and Mechanism Study of Kel As an Oncogenic Driver in Acute Erythroleukemia

The Synergy of Vitamin C with Decitabine Activates TET2 in Leukemic Cells and Significantly Improves Overall Survival in Elderly Patients with Acute Myeloid Leukemia

TP53-Induced Glycolysis and Apoptosis Regulator Protects from Spontaneous Apoptosis and Predicts Poor Prognosis in Chronic Lymphocytic Leukemia

Baseline Characteristics and Early Monitoring of Chinese CML Patients Treated with Dasatinib: Report from a Multicenter, Observational, Registry-Based Study

PFKFB3 Is a Crucial Target in the Treatment of Tyrosine Kinase Inhibitor Resistant Chronic Myelogenous Leukemia

Continuous High-Dose Idarubicin and Busulfan As Conditioning Regimen for Chinese Patients with Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation

Decitabine, low-dose cytarabine and aclarubicin combination with granulocyte colony-stimulating factor priming for the induction chemotherapy of older patients with myelodysplastic syndromes and acute myeloid leukemia

Effect of Low-Dose Cytarabine and Aclarubicin in Combination with Decitabine and Granulocyte Colony-Stimulating Factor Priming on the Outcome of Patients with Myeloid neoplasms

Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses.

High-Dose Etoposide with Granulocyte Colony-Stimulating Factor for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Hematologic Malignancies.

Cotransplantation of HLA-Identical Mesenchymal Stem Cells and Hematopoietic Stem Cells in Chinese Patients with Hematologic Diseases.

HLA-Haploidentical Related Hematopoietic Stem Cell Transplantation and Mesenchymal Stem Cell Transplantation in Patients with Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only